In a report released today, Gil Blum from Needham maintained a Buy rating on Immunocore Holdings (IMCR – Research Report), with a price target of $71.00.
Gil Blum has given his Buy rating due to a combination of factors that highlight Immunocore Holdings’ promising future. The company has shown strong performance with its Kimmtrak sales, which were in line with expectations for the fourth quarter and full year of 2024. The anticipated growth in Kimmtrak sales for 2025, driven by increased penetration in the U.S. market and expansion into new territories, supports a positive outlook for the company’s revenue.
Additionally, the ongoing developments in Immunocore’s pipeline, such as the Phase I HIV study and the PRISM-MEL-301 study, indicate potential for future advancements and success in their treatment offerings. The company’s robust cash position at the end of 2024 further strengthens its financial stability, providing a solid foundation for continued investment in research and development. These elements collectively underpin Gil Blum’s decision to maintain a Buy rating and a price target of $71 for Immunocore Holdings.
Blum covers the Healthcare sector, focusing on stocks such as Geron, Sarepta Therapeutics, and Cartesian Therapeutics. According to TipRanks, Blum has an average return of -9.7% and a 32.80% success rate on recommended stocks.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $60.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com